Cassava Sciences has given up on simufilam in Alzheimer’s disease. | Cassava Sciences has given up on simufilam in ...

Cassava stock crashes 32% as its investigational Alzheimer's disease drug fails to meet the prespecified co-primary endpoints ...

Cassava Sciences is ending simufilam development for Alzheimer's after Phase 3 trials failed. The company is shifting focus ...

Cassava Technologies is set to roll out Nvidia’s artificial intelligence software at its South African data centers by June, ...

Cassava said that it will discontinue all efforts to develop simufilam and expects to phase out the program by the end of the second quarter. Still, the biotechnology company said it has begun ...

A research team investigates how genome editing can be harnessed to accelerate cassava breeding and improve key traits.

Headquartered in the UK, Cassava has a presence across Africa, the Middle East, Latin America and the United States. Through ...

Cassava Technologies and Nvidia will collaborate to power Africa’s first artificial intelligence factory. Nvidia Corp. has ...

The U.S. Food and Drug Administration approved Soleno Therapeutics' drug to treat a rare genetic disorder on Wednesday, ...

President Donald Trump continues to warn of tariffs on the pharmaceutical industry; Susan Monarez replaces Dave Weldon as CDC ...

Cassava Technologies is building a new supercomputer in South Africa as part of what it claims is Africa’s “first AI factory.